Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Depreciation & Amortization (CF) (2018 - 2025)

Bicycle Therapeutics' Depreciation & Amortization (CF) history spans 8 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 21.6% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $6.4 million, down 10.48%, while the annual FY2025 figure was $6.4 million, 10.48% down from the prior year.
  • Depreciation & Amortization (CF) reached $1.3 million in Q4 2025 per BCYC's latest filing, down from $1.8 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.2 million in Q3 2024 to a low of $325000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $1.3 million, with a median of $1.6 million recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): surged 275.07% in 2022, then fell 21.6% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $407000.0 in 2021, then skyrocketed by 240.54% to $1.4 million in 2022, then increased by 19.34% to $1.7 million in 2023, then grew by 3.02% to $1.7 million in 2024, then dropped by 21.6% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Depreciation & Amortization (CF) are $1.3 million (Q4 2025), $1.8 million (Q3 2025), and $1.7 million (Q2 2025).